Skip to main content
SpringerLink
Log in

Dissemination Control of the Antimicrobial Resistance in the Intensive Care Unit

  • Chapter
Sepsis

  • 1156 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Howard D, Cordell R, McGowan JE, Jr., et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis 2001;33:1573–8.

    Article  PubMed  CAS  Google Scholar 

  2. McGowan JE, Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001;7:286–92.

    PubMed  Google Scholar 

  3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481–98.

    Google Scholar 

  4. Chaix C, Durand-Zaleski I, Alberti C, et al. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745–51.

    Article  PubMed  CAS  Google Scholar 

  5. Saulnier FF, Hubert H, Onimus TM, et al. Assessing excess nurse work load generated by multiresistant nosocomial bacteria in intensive care. Infect Control Hosp Epidemiol 2001;22:273–8.

    Article  PubMed  CAS  Google Scholar 

  6. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002;23:106–8.

    Google Scholar 

  7. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146–55.

    Article  PubMed  CAS  Google Scholar 

  8. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–74.

    Article  PubMed  CAS  Google Scholar 

  9. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486–94.

    PubMed  CAS  Google Scholar 

  10. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000;30:870–6.

    Article  PubMed  CAS  Google Scholar 

  11. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 2002;8:347–54.

    Article  PubMed  Google Scholar 

  12. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247–50.

    Article  PubMed  CAS  Google Scholar 

  13. Danes C, Navia MM, Ruiz J, et al. Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother 2002;50:261–4.

    Article  PubMed  CAS  Google Scholar 

  14. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002;49:229–33.

    Article  PubMed  CAS  Google Scholar 

  15. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998;27Suppl 1:S117–24.

    PubMed  CAS  Google Scholar 

  16. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379–82.

    PubMed  CAS  Google Scholar 

  17. Rasmussen BA, Bradford PA, Quinn JP, et al. Genetically diverse ceftazidimeresistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother 1993;37:1989–92.

    PubMed  CAS  Google Scholar 

  18. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415–22.

    PubMed  Google Scholar 

  19. Muller A, Lopez-Lozano JM, Bertrand X, et al. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004;54:173–7. Epub 2004 May 18.

    Article  PubMed  CAS  Google Scholar 

  20. Wang H, Kelkar S, Wu W, et al. Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother 2003;47:790–3.

    Article  PubMed  CAS  Google Scholar 

  21. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1:101–14.

    Article  PubMed  CAS  Google Scholar 

  22. Shlaes DM, Gerding DN, John JF, Jr., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–99.

    PubMed  CAS  Google Scholar 

  23. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64–8.

    Article  PubMed  CAS  Google Scholar 

  24. Ministere de la solidarite. 100 Recommandations pour la surveillance at la prevention des infections nosocomiales. Paris, 1999.

    Google Scholar 

  25. Trick WE, Weinstein RA, DeMarais PL, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc 2001;49:270–6.

    Article  PubMed  CAS  Google Scholar 

  26. Pirwitz S. HICPAC guidelines for isolation precautions: Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1997;25:287–8.

    Article  PubMed  CAS  Google Scholar 

  27. Scully BE, Briones F, Gu JW, et al. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med 1992;152:353–6.

    Article  PubMed  CAS  Google Scholar 

  28. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871–7.

    Article  PubMed  CAS  Google Scholar 

  29. Farr BM, Salgado CD, Karchmer TB, et al. Can antibiotic-resistant nosocomial infections be controlled? Lancet Infect Dis 2001;1:38–45.

    Article  PubMed  CAS  Google Scholar 

  30. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1–13.

    Google Scholar 

  31. Gross PA, Pujat D. Implementing practice guidelines for appropriate antimicrobial usage: a systematic review. Med Care 2001;39:II55–69.

    PubMed  CAS  Google Scholar 

  32. Perez A, Dennis RJ, Rodriguez B, et al. An interrupted time series analysis of parenteral antibiotic use in Colombia. J Clin Epidemiol 2003;56:1013–20.

    Article  PubMed  Google Scholar 

  33. Geissler A, Gerbeaux P, Granier I, et al. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Intensive Care Med 2003;29:49–54.

    PubMed  Google Scholar 

  34. Bisson G, Fishman NO, Patel JB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002;23:254–60.

    Article  PubMed  Google Scholar 

  35. Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001;14:711–5.

    PubMed  CAS  Google Scholar 

  36. Sanders WE, Sanders CC. Cycling of antibiotics: an approach to circumvent resistance in specialized units of the hospital. Clin Microbiol Infect 1996;1:223–5.

    PubMed  Google Scholar 

  37. John JF, Jr. Antibiotic cycling: is it ready for prime time? Infect Control Hosp Epidemiol 2000;21:9–11.

    Article  PubMed  Google Scholar 

  38. Sandiumenge A, Rello J. [Cyclic rotation of antibiotics. Is all that glitters gold?]. Enferm Infecc Microbiol Clin 2003;21:93–100.

    Article  PubMed  Google Scholar 

  39. Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus beta-lactamaminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2002:CD003038.

    Google Scholar 

  40. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519–27.

    Article  PubMed  Google Scholar 

  41. Lewis D. Antimicrobial resistance surveillance: methods will depend on objectives. J Antimicrob Chemother 2002;49:3–5.

    Article  PubMed  CAS  Google Scholar 

  42. Gerding DN, Larson TA, Hughes RA, et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:1284–90.

    PubMed  CAS  Google Scholar 

  43. Patterson JE. Extended-spectrum beta-lactamases. Semin Respir Infect 2000;15:299–307.

    Article  PubMed  CAS  Google Scholar 

  44. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933–51, table of contents.

    Article  PubMed  CAS  Google Scholar 

  45. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003;53:39–45.

    Article  PubMed  Google Scholar 

  46. Lynch JP, 3rd. Antimicrobial resistance: it’s time to reverse the trend. Chest 2001;119:371S–2S.

    Article  PubMed  Google Scholar 

  47. Phillips I, Shannon K. Importance of beta-lactamase induction. Eur J Clin Microbiol Infect Dis 1993;12Suppl 1:S19–26.

    Article  PubMed  CAS  Google Scholar 

  48. Mulgrave L. The changing ecology of hospital bacteria and the selective role of cephalosporins. Epidemiol Infect 1991;106:121–32.

    Article  PubMed  CAS  Google Scholar 

  49. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–77.

    Article  PubMed  Google Scholar 

  50. Guyot A, Barrett SP, Threlfall EJ, et al. Molecular epidemiology of multi-resistant Escherichia coli. J Hosp Infect 1999;43:39–48.

    Article  PubMed  CAS  Google Scholar 

  51. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48:224–8.

    Article  PubMed  CAS  Google Scholar 

  52. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and thirdgeneration cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135:175–83.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectology Unit, Hospital Universitario San Ignacio, Bogotá, Colombia

    Carlos Arturo Alvarez MD (Chief) & Jorge Alberto Cortés MD

  2. Department of Internal Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia

    Carlos Arturo Alvarez MD (Chief) & Jorge Alberto Cortés MD

Authors
  1. Carlos Arturo Alvarez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Alberto Cortés MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pulmonary and Critical Care Medicine, Universidad del Bosque, Bogotá, Colombia

    Guillermo Ortiz-Ruiz MD

  2. Intensive Care Unit, Fundacion Clinica Shaio, Bogotá, Colombia

    Marco A. Perafán MD

  3. Department of Surgery Klinikum Grosshadern, University of Munich, Munich, Germany

    Eugen Faist MD

  4. Pulmonary and Critical Care Medicine, Hospital Bocagrande, Cartagena, Colombia

    Carmelo Dueñas Castell MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Alvarez, C.A., Cortés, J.A. (2006). Dissemination Control of the Antimicrobial Resistance in the Intensive Care Unit. In: Ortiz-Ruiz, G., Perafán, M.A., Faist, E., Castell, C.D. (eds) Sepsis. Springer, New York, NY. https://doi.org/10.1007/0-387-34574-4_4

Download citation

  • DOI: https://doi.org/10.1007/0-387-34574-4_4

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-29816-0

  • Online ISBN: 978-0-387-34574-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation